NCT01583283 is a Phase 1 clinical trial of ACY-1215 in Multiple Myeloma, sponsored by Celgene.

Who is sponsoring NCT01583283?

NCT01583283 is sponsored by Celgene.

What drugs are being tested in NCT01583283?

Interventions in NCT01583283: ACY-1215, lenalidomide, Dexamethasone.

What condition does NCT01583283 study?

NCT01583283 studies Multiple Myeloma.

Is NCT01583283 still recruiting?

NCT01583283 is currently completed. Last updated 23 February 2022.

Last reviewed 2022-02-23 · How we verify

NCT01583283

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Completed Phase 1 Last updated 23 February 2022

What this trial tests

Phase 1 trial testing ACY-1215 in Multiple Myeloma in 38 participants. Completed in 24 March 2021.

Timeline

12 July 2012

Primary endpoint
15 March 2021

24 March 2021

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	12 July 2012
Primary completion	15 March 2021
Estimated completion	24 March 2021
Sites	5 locations across United States

Drugs / interventions tested

ACY-1215 — full drug profile →
lenalidomide — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the best dose of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Once determined, the purpose of this study will be to determine the efficacy of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma who have had 1-3 prior therapies and who are not lenalidomide-refractory.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Histone deacetylase 6 in cancer.
Li T, Zhang C, Hassan S, Liu X, et al · · 2018 · cited 261× · PMID 30176876 · DOI 10.1186/s13045-018-0654-9
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.
Li G, Tian Y, Zhu WG. · · 2020 · cited 246× · PMID 33117804 · DOI 10.3389/fcell.2020.576946
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT, Raje N, Jagannath S, Richardson P, et al · · 2017 · cited 207× · PMID 28053023 · DOI 10.1158/1078-0432.ccr-16-2526
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ, Bensinger WI, Supko JG, Voorhees PM, et al · · 2016 · cited 155× · PMID 27646843 · DOI 10.1016/s1470-2045(16)30375-8
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials.
Hontecillas-Prieto L, Flores-Campos R, Silver A, de Álava E, et al · · 2020 · cited 145× · PMID 33024443 · DOI 10.3389/fgene.2020.578011
The role of epigenetics in the biology of multiple myeloma.
Dimopoulos K, Gimsing P, Grønbæk K. · · 2014 · cited 100× · PMID 24786391 · DOI 10.1038/bcj.2014.29
Promising therapies in multiple myeloma.
Bianchi G, Richardson PG, Anderson KC. · · 2015 · cited 69× · PMID 26031917 · DOI 10.1182/blood-2015-03-575365
Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.
Gatla HR, Muniraj N, Thevkar P, Yavvari S, et al · · 2019 · cited 68× · PMID 30841513 · DOI 10.3390/ijms20051110

Verify or expand the search:

Other trials of ACY-1215

Trials testing the same drug.

NCT02632071 — ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer · Phase 1 · completed
NCT02091063 — ACY-1215 for Relapsed/Refractory Lymphoid Malignancies · Phase 1, PHASE2 · terminated

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01583283 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 23 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01583283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing